Study Title
 |
Principal
Investigator |
Disease
Category |
 |
|
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
|
Laura Johnston
|
Myeloproliferative Disorders
Leukemia
Lymphoma
Graft vs Host Disease
Myelodysplastic Syndromes
Multiple Myeloma
|
|
|
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma
|
Michael Link
|
Lymphoma
Lymphoma, Non-Hodgkin
|
|
|
Reduced Duration Standford V Chemotherapy With Low-Dose Tailored-Field Radiation For Favorable Risk Pediatric Hodgkin Lymphoma
|
Michael Link
|
Lymphoma
|
|
|
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
|
Steven Edward Coutre
|
Multiple Myeloma
Bone Diseases
|
|
|
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-Cell Lymphoma
|
Youn H Kim
|
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
|
|
|
Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy
|
Ronald Levy
|
Lymphoma
|
|
|
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
|
Sandra Jeane Horning
|
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
|
|
|
Donor Stem Cell Transplant in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma After First Complete Remission
|
Ginna Laport
|
Lymphoma
Lymphoma, Non-Hodgkin
|
|
|
A Phase II Intratumoral Injection PF-3512676 plus Local Radiation in Low-Grade B-Cell Lymphomas
|
Ronald Levy
|
Lymphoma
|
|
|
A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma
|
Sandra Jeane Horning
|
Lymphoma, Hodgkin Disease
Hodgkin Disease
|
|
|
Ph II, Multicenter, Simon 2-Stage of R788 For Relapsed or Refractory T-Cell Lymphoma
|
Ranjana Hira Advani
|
Lymphoma, T-Cell
|
|
|
Phase I Dose-Escalation Study of Btk Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
|
Ranjana Hira Advani
|
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic
Lymphoma, Small-Cell
|
|
|
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
|
Steven Edward Coutre
|
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic
|
|
|
Safety and Efficacy of RAD001 in Patients With Velcade® Refractory Mantle Cell Lymphoma
|
Ranjana Hira Advani
|
Lymphoma, Mantle-Cell
|
|
|
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST)
|
Steven Edward Coutre
|
Multiple Myeloma
|
|
|
Ph II of Single-Agent Enzastaurin for Relapsed Cutaneous T-Cell Lymphoma
|
Youn H Kim
|
Lymphoma, T-Cell
|
|
|
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
|
Steven Edward Coutre
|
Leukemia
Leukemia, Myeloid
Leukemia, Myelocytic, Acute
Lymphoma, T-Cell, Cutaneous
|
|
|
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Second-Line Treatment of Patients With DLBCL
|
Ranjana Hira Advani
|
Lymphoma, Diffuse
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
|
|
|
Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Lymphoproliferative Malignancies
|
Ranjana Hira Advani
|
Lymphoma, Hodgkin Disease
Hodgkin Disease
Lymphoma, Non-Hodgkin
|
|
|
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
|
Youn H Kim
|
Lymphoma, T-Cell
|
|
|
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
Youn H Kim
|
Lymphoma, T-Cell, Cutaneous
|
|
|
Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
|
Susan J Knox
|
Lymphoma, Non-Hodgkin
|
|
|
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
|
Youn H Kim
|
Lymphoma, T-Cell, Cutaneous
|
|
|
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
|
Sandra Jeane Horning
|
Lymphoma
Lymphoma, Hodgkin Disease
Hodgkin Disease
|
|
|
Phase III CHOP + Rituximab vs CHOP + Iodine-131 Monoclonal Anti-B1 Antibody for New Dx Foll NHL
|
Sandra Jeane Horning
|
Lymphoma
|
|
|
Phase II study of Atorvastatin safety and antitumor effects in non-Hodgkin's Lymphoma
|
Dean Felsher
|
Leukemia
Lymphoma, Non-Hodgkin
|
|
|
Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
|
Susan J Knox
|
Lymphoma, Non-Hodgkin
Lymphoma, Large-Cell, Diffuse
|
|
|
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
|
Sandra Jeane Horning
|
Lymphoma
Lymphoma, Hodgkin Disease
Hodgkin Disease
|
|
|
Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)
|
Sandra Jeane Horning
|
Lymphoma, B-Cell
|
|
|
Therapy for Pediatric Hodgkin Lymphoma
|
Michael Link
|
Lymphoma, Hodgkin Disease
Hodgkin Disease
|
|
|
Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
|
Ranjana Hira Advani
|
Lymphoma, T-Cell
|
|
|
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
|
Sandra Jeane Horning
|
Brain Cancer
Lymphoma
|
|
|
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin's Disease
|
Michael Link
|
Lymphoma
|
|
|
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
|
Youn H Kim
|
Lymphoma
Lymphoma, Non-Hodgkin
|
|
|
A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL
|
Sandra Jeane Horning
|
Lymphoma, Hodgkin Disease
Hodgkin Disease
Blood Cancer
|
|
Study Title
|
Principal
Investigator |
Disease
Category |
|
|
Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
|
Wen-Kai Weng
|
Transplantation, Homologous
Transplantation, Autologous
Multiple Myeloma
|
|
|
Ph II of Non-myeloablative Allgnc Trnsplnt Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Wen-Kai Weng
|
Sezary Syndrome
Mycoses
Lymphoma, T-Cell, Cutaneous
|
|
|
Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL
|
Ronald Levy
|
Lymphoma, Mantle-Cell
|
|
|
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
|
Ronald Levy
|
Lymphoma, Non-Hodgkin
|
|
|
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
|
Robert S Negrin
|
Multiple Myeloma
|
|
|
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
|
Wen-Kai Weng
|
Lymphoma, Non-Hodgkin
|
|
|
Bone Marrow Grafting for Leukemia and Lymphoma
|
Robert S Negrin
David Miklos
|
Leukemia
Lymphoma
Hematologic Diseases
|
|
|
Study of Late-Occurring Complications in Childhood Cancer Survivors
|
Dr. Neyssa Marina
|
Leukemia
Sarcoma
Retinoblastoma
Lymphoma
Retinal Neoplasms
|
|
|
Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
|
Robert S Negrin
Judith Anne Shizuru
|
Leukemia, Myeloid
Lymphoma, Non-Hodgkin
Multiple Myeloma
|
|
|
NMDP Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
|
David Miklos
|
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic
Multiple Myeloma
|
|
Study Title
|
Principal
Investigator |
Disease
Category |
|
Rituximab in Treating Patients With Hodgkin's Lymphoma
(No longer recruiting)
|
Sandra Jeane Horning
|
Lymphoma
|
|
Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma
(No longer recruiting)
|
Sandra Jeane Horning
|
Lymphoma
|
|
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated w/RCHOP +/- XRT
(No longer recruiting)
|
Kristen N. Ganjoo
|
Lymphoma
Lymphoma, Non-Hodgkin
|
|
An Open Label Six Month Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.04% Ointment Formulation in Patients With Stage I or IIA Mycosis Fungoides (MF) Who Have Completed an Initial 12 Month Treatment With Nitrogen Mustard 0.02% But Without a Complete Response
(inv )
|
Youn H Kim
|
Mycosis Fungoides
|
|
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
(No longer recruiting)
|
Kristen N. Ganjoo
|
Lymphoma, Non-Hodgkin
|
|
Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
(Terminated)
|
Sandra Jeane Horning
|
Lymphoma, B-Cell
Reticuloendotheliosis
Histiocytosis
Lymphoma, Large-Cell, Diffuse
|
|
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
(Terminated)
|
Ronald Levy
|
Lymphoma, Non-Hodgkin
Lymphoma, Follicular
|
|
Phase 1/2 Study of VELCADE®, Dexamethasone, and Revlimid® Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid in Patients With Previously Untreated Multiple Myeloma (EVOLUTION)
(Completed)
|
Bruno Carneiro de Medeiros
|
Multiple Myeloma
|
|
A Dose and Schedule Finding Trial With AMG 531 for CIT in Adults With Lymphoma
(Completed)
|
Ranjana Hira Advani
|
Lymphoma
Thrombocytopenia
Lymphoma, Non-Hodgkin
|
|
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
(No longer recruiting)
|
Sandra Jeane Horning
|
Lymphoma
|
|
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
(No longer recruiting)
|
Ranjana Hira Advani
|
Lymphoma
|
|
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
(Completed)
|
Dr. Neyssa Marina
|
Lymphoma
|
|
Combination Chemotherapy in Treating Children or Adolescents With Newly Diagnosed Stage III or Stage IV Lymphoblastic Lymphoma
(Completed)
|
Dr. Neyssa Marina
|
Lymphoma
|
|
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined with Local Radiation for Patients with Recurrent Mycosis Fungoides.
(Terminated)
|
Ronald Levy
|
Mycosis Fungoides
|
|
Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
(No longer recruiting)
|
Ronald Levy
|
Lymphoma, Non-Hodgkin
|
|
Mixed Chimera Allo Transplantation in Multiple Myeloma
(No longer recruiting)
|
Wen-Kai Weng
|
Blood Cancer
Multiple Myeloma
|
|
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
(Completed)
|
Robert Lowsky
|
Multiple Myeloma
|
|
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
(Completed)
|
Ronald Levy
|
Multiple Myeloma
|
|
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
(No longer recruiting)
|
Sally Arai
|
Leukemia
Multiple Myeloma
|
|
High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
(No longer recruiting)
|
Sally Arai
|
Multiple Myeloma
|
|
Allo BMT in Advanced Leukemia or High Grade Lymphoma
(No longer recruiting)
|
Robert Lowsky
|
Lymphoma, Non-Hodgkin
|
|
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
(No longer recruiting)
|
Robert S Negrin
|
Lymphoma, Non-Hodgkin
|
|
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
(No longer recruiting)
|
Wen-Kai Weng
|
Lymphoma, Non-Hodgkin
|
|
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma
(No longer recruiting)
|
Sandra Jeane Horning
|
Lymphoma
|
|
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-Cell Lymphoma
(No longer recruiting)
|
Youn H Kim
|
Mycosis Fungoides
Lymphoma, T-Cell, Cutaneous
|
|
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
(No longer recruiting)
|
Youn H Kim
|
Mycosis Fungoides
|
|
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
(No longer recruiting)
|
Gary V Dahl
|
Leukemia
Lymphoma
Tumor Lysis Syndrome
Hyperuricemia
|
|
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
(No longer recruiting)
|
Ranjana Hira Advani
|
Lymphoma, T-Cell, Peripheral
|
|
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
(No longer recruiting)
|
Dr. Neyssa Marina
|
Leukemia
Lymphoma
Neuroblastoma
Medulloblastoma
|
|
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
(No longer recruiting)
|
Kristen N. Ganjoo
|
Lymphoma
|
|
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
(Completed)
|
Steven Edward Coutre
|
Leukemia
Waldenstrom Macroglobulinemia
Lymphoma, Non-Hodgkin
Multiple Myeloma
|
|
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
(No longer recruiting)
|
Sandra Jeane Horning
|
Lymphoma
|
|
Bortezomib, Ifosfamide, and Vinorelbine in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
(Suspended)
|
Dr. Neyssa Marina
|
Lymphoma
|
|
Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma
(No longer recruiting)
|
Ranjana Hira Advani
|
Lymphoma, B-Cell
|
|
Study of Intravenously Administered SNS-032 in Patients With Advanced B-Lymphoid Malignancies
(No longer recruiting)
|
Steven Edward Coutre
|
Leukemia, Lymphocytic, Chronic
Multiple Myeloma
|
|
Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma
(No longer recruiting)
|
Sandra Jeane Horning
|
Lymphoma
Lymphoma, Mantle-Cell
|
|
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
(Completed)
|
Sandra Jeane Horning
|
Lymphoma, Non-Hodgkin
|
|
Ph 3 Open-label KOS953+Bortezomib compared to Bortezomib for First Relapse MM
(Suspended)
|
Bruno Carneiro de Medeiros
|
Multiple Myeloma
|
|
Trial Administration